biospecimen banks

CPDR Patient Education Program

Industry-Sponsored Clinical Trials and Projects

The CRC maintains a comprehensive portfolio of both investigator-initiated and industry sponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, are investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. All trials and projects are carried out with full approval of the respective IRBs.

 

CPDR Open Clinical Trials


  1. ProstAtak Trial

    A randomized trial of ProstAtak in combination with standard external beam radiation therapy with or without androgen deprivation therapy is in men with intermediate to high risk localized prostate cancer. ProstAtak is an investigational product that is meant to kill tumor cells and elicit an anti-tumor vaccine effect. In a Phase II clinical trial of ProstAtak given with radiation, prostate cancer recurrence was three-fold lower than typically seen with radiation alone. The purpose of this Phase III trial is to definitively determine if ProstAtak reduces prostate cancer recurrence

     

  2. BAYER - RADIUM 223

    A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride (radium 223 dichloride is FDA approved drug that targets prostate cancer in the bones), in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer

     

  3. AMOR3-SV

    A phase 3, randomized, open-label, multi-center, controlled study of Galeterone compared to Enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) with metastatic (M1) castrate resistant prostate cancer (CRPC). Galeterone is a selective, multi-targeted, small molecule drug for the treatment of castrate resistant prostate cancer

     

CONTACT Information: Judith A. Travis, RN, Walter Reed National Military Medical Center, Center for Prostate Disease Research, America Building 19, Room 3225 on the 3rd floor.
301-319-2927 or Judith.a.travis.ctr@mail.mil

WRNMMC UsToo!

Guest Speaker Program


Dr. David

Dr. Jim David

Board certified psychotherapist in private practice treating individuals, couples and families

Presentation: "The ABC’s of Self-Care"

Date: Thursday 2 Feb 2017
Time: 1900-2030
Location: Walter Reed National Military Medical Center (America Building, 2nd floor, Room 2525) and Fort Belvoir Community Hospital (via video teleconference in Oaks Pavilion, 1st floor, Room 332).

A military ID card is required to get on base at Walter Reed. Attendees without a military ID need to call the Prostate Center at 301-319-2900 at least 4 business days in advance to complete paperwork for gate access approval. Also bring some form of picture identification at the gate.

Snow day: If the federal government is closed the day of the presentation, the program is cancelled. If the federal government has a delayed opening that day, the show will go on! Call the Prostate Center at 301-319-2900 if you have any questions.

 

Read the January 2017 CPDR E-Newsletter

Read the NOVEMBER 2016 WRNMMC UsToo! Newsletter

Go to the WRNMMC UsToo! Newsletter Archive or 2016 CPDR E-Newsletter Archive




NEWS


June 23, 2016

by Paula Amann
Published in the June 2016 issue of Military Medical Research News, a monthly newsletter of the Department of Research Programs, Walter Reed National Military Medical Center.

Fine-tuning facial transplants, predicting bone fractures, shrinking prostate cancers with new drugs and cutting the costs of surgical training with the right technology: These were among the problems probed by competition winners for 2016 Research and Innovation Month at Walter Reed National Military Medical Center (WRNMMC).

RAP winners included LT Daniel Griffin, MC (resident laboratory category); CPT Sarah Placek, MC (resident clinical); Charles P. Xavier, Ph.D. (staff laboratory); and Benjamin Sheffield (staff clinical).

Read Full Article